Pharma BD Deal Intelligence
An early-stage discovery collaboration, not yet a proven win: AbbVie paid EvolveImmune just $65 million upfront against up to $1.4 billion in potential milestones for multispecific T-cell engager platform rights, with the first program reaching development-candidate selection only in April 2026.
AbbVie and EvolveImmune partner to develop multispecific cancer biotherapeutics; discovery-stage platform with no disclosed clinical candidates yet
AbbVie and EvolveImmune strike deal to develop biotherapeutics for resistant cancer cells.
$18 million milestone payment to EvolveImmune triggered by nomination of a development candidate targeting a solid tumor under the AbbVie collaboration; first…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
On October 31, 2024, AbbVie entered a multi-year discovery collaboration and option-to-license agreement with privately held EvolveImmune Therapeutics to develop next-generation, multispecific T-cell engager biotherapeutics for solid and hematologic malignancies. EvolveImmune received $65 million in aggregate upfront fees and equity investment from AbbVie and is eligible for up to $1.4 billion in aggregate option fees and milestones, plus tiered royalties on net sales. The partnership leverages EvolveImmune's proprietary EVOLVE platform, which incorporates integrated T-cell co-stimulation designed to amplify and sustain tumor-killing capacity against immunologically 'cold' tumors. On April 28, 2026, the collaboration reached its first development milestone: the nomination of a development candidate against a solid-tumor target — the first program from the partnership to reach candidate selection — triggering an $18 million milestone payment to EvolveImmune. Separately, EvolveImmune is advancing its wholly owned lead asset EVOLVE104 (a trispecific T-cell engager) into a Phase 1a/1b trial following FDA IND clearance in August 2025.
1.9M US cases/yr · $12.5B Global Bispecific Antibody Market (2024) · $65M AbbVie Upfront (fees + equity)
T-cell engager therapies redirect the patient's own T cells to attack cancer cells by binding both a tumor antigen and a T-cell receptor component (typically CD3). EvolveImmune's EVOLVE platform differentiates by incorporating integrated T-cell co-stimulation signals, which amplify and sustain T-cell killing capacity. This approach targets immunologically 'cold' solid tumors where current immunotherapies fail.
EvolveImmune's proprietary EVOLVE platform delivers potent, selective T-cell co-stimulation alongside tumor engagement, enhancing T-cell fitness and overcoming resistance in cold solid tumor models. AbbVie gains options on multiple targets with up to $1.4B in milestones. First-in-human trials anticipated in 2025.
AbbVie Inc. completed its acquisition of EvolveImmune Therapeutics Inc. for $1.5B. CORRECTION: The originally referenced AbbVie/Harpoon deal ($510M, announced 2019, option not exercised in 2023) did not reach $1.4B.
EvolveImmune nominated a development candidate against a solid-tumor target under the AbbVie collaboration, the first program from the October 2024 partnership to reach candidate selection, triggering an $18 million milestone payment.
Preclinical T-cell engager programs. Recently signed. Discovery phase. Assessment of AbbVie Inc.'s $1.5B acquisition of EvolveImmune Therapeutics Inc. and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / EvolveImmune Therapeutics Inc. (this deal) | 2024 | $1.5B | 59 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2024 deals · AbbVie Inc. deals · Oncology deals